Member Info for Timster

Noticed it's in the antibody drug conjugate section on top of the poster board.

Have they sneaked an antibody in there like Alan did with the LFT 😏

Https://x.com/avacta/status/1849418466412863543?t=dfS81sVTmIgxv1F8cF2CeA&s=19

Remember that image those BB members who keep saying it's a presentation.

All that means is that wynbore has bought in, he'll be back to fud essays when he's out again.

Conclusions from the poster:

AVA6103 is a novel peptide drug conjugate (PDC) based on proprietary pre|CISION® technology which incorporates a dipeptide that is specifically cleaved by Fibroblast Activation Protein α (FAP) which results in tumor-specific delivery of the exatecan warhead directly to tumor cells uUsing AVA6103Gen Two pre|CISION® compounds, characterized by varying two key pieces of the chemical structure of pre|CISION® exatecan (the capping group [A] and self-immolative linker [B]), we can modulate both FAP enzyme efficiency (kcat/Km) and the PK properties of each compound–The therapeutic index of exatecan is significantly increased by pre|CISION®enabling, specifically the MTD of compound 1 was 75 times that of conventional exatecan in a daily dosing regimen –

AVA6103 optimizes the bystander effect, where the conjugate is only cleaved by FAP+ fibroblasts, and released exatecan can enter FAP- cancer cells uIn a Patient-derived xenograft model, high intratumoral warhead concentrations are seen at 4hr and 24hr timepoints for several pre|CISION® exatecan compounds, with up to 50-fold higher warhead concentrations in the tumor vs. plasma

pre|CISION® exatecan demonstrates tumor growth inhibition in an efficacy study, where HEK-FAP tumors treated with Compound 1 displayed no growth over a three-week period, and increased survival vs. vehicle treated tumors

50 fold concentrate in tumour, also massive!!

Countach,bloody spell checker 😁

Have you got the Lamborghini contact one or the tennis girl poster you could move them up a bit.

Https://avacta.com/wp-content/uploads/2024/10/FAP-AFFDC_Poster_SS44.09-2_v1.3-FINAL.pdf

Https://avacta.com/wp-content/uploads/2024/10/EORTC-NCI-AACR-poster-AVP103-v1_SS44.09_V1.1-updated-18.10.24-003.pdf

And that is what the day planned for the 30th is aimed to attract @olderwiser

Hence the massive 7%, couldn't make it up really, this update on the Nasdaq would have the yanks going mental, bagels and cwaffee spilled on the trading floor....

The usual, as amazing as this is it won't actually make money (if Avacta keep hold of it) for years.

BUT the important thing is the audience and meetings that come off the back of the data.

Awesome

https://x.com/coughlin582/status/1849359772018962845?t=Ic7LPyYAOauDUZ2NveUPnQ&s=19

Got to actually give it to Alan, getting exclusive rights to affimers will prove to be a good thing.

Incredible data, big farmer will be scratching his beard and having a think this morning.

Great stuff, still works then. As you say SP drop today 😁

Https://polaris.brighterir.com/public/avacta/news/rns/story/xl4p7gr

Company will present new preclinical data on two breakthroughs in the pre|CISION™ platform in poster sessions at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain from 23-25 October 2024

No need PL75, IPO in 3 weeks......

It's a poster, I doubt they'll RNS, it'll just be published on the website.

It's a sell every payment the board is the same.

Once they are clear it will be just as Hurst predicted, size buyers move in 70-80 testedm